NCT03392389已完成1 期
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus and Human Parainfluenza Virus Type 3 Vaccine, When Administered to Healthy Adults
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 124
- 试验地点
- 5
- 主要终点
- Proportion of subjects who achieve serum anti-hMPV and anti-PIV3 neutralizing antibody titers greater than the third quartile of the serum anti-hMPV and anti-PIV3 antibody titers overall distribution at baseline
研究概览
简要总结
This clinical study will assess the safety, reactogenicity and immunogenicity of mRNA-1653, a combined human metapneumovirus and human parainfluenza virus type 3 vaccine in healthy adults.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Prevention
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 49 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Agrees to comply with the study procedures and provides written informed consent
- •18 to 49 years of age
- •Body mass index between 18 and 35 kg/m2
- •In good health based on medical history, physical examination, vital sign measurements and laboratory safety tests performed prior to initial study vaccination
- •Negative urine pregnancy test at the screening visit and the day of each vaccination for females of childbearing potential
- •Female subjects must either be of non-childbearing potential or use acceptable methods of contraception from at least 30 days prior to enrollment and through 3 months following last vaccination
- •Willing to comply with the requirements of the protocol (eg, complete Diary Cards, return for follow-up visits, be available for safety phone calls)
排除标准
- •Any ongoing, symptomatic acute or chronic illness requiring medical or surgical care
- •A history of malignancy in the last 10 years
- •If female and of childbearing potential, is pregnant or lactating, has not adhered to an adequate contraception method from at least 30 days before study entry, or does not plan to do so for at least 3 months after the last vaccination
- •Abnormal screening safety laboratory test results including liver enzyme tests
- •Administration of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the first dose of study vaccine or has plans for administration during the study period
- •Prior administration of investigational agent using lipid nanoparticle formulations
- •A positive test result for hepatitis B surface antigen, hepatitis C virus antibody, or human immunodeficiency virus types 1 or 2 antibodies
- •A positive test result for drugs of abuse
- •Chronic administration of potentially hepatotoxic drugs or have other medical conditions that affect the liver (eg, alcohol abuse)
- •A history of idiopathic urticaria
- •Plans for administration or has been administered a vaccine within the period from 30 days before through 30 days after each study vaccination, with the exception of any licensed influenza vaccine administered ≥15 days before or after any study vaccination
- •Any chronic administration of an immunosuppressant or other immune modifying drug
- •Prior administration of immunoglobulins and/or any blood products within the 3 months before the first study vaccine or has plans for administration during the study period
- •Any known or suspected immune-mediated disease or immunosuppressive condition as determined by medical history and/or physical examination
- •A history of hypersensitivity or serious reactions to previous vaccinations
- •Any bleeding disorder considered a contraindication to IM injection or blood draw
- •Any acute illness or fever at screening
- •Any condition that, in the opinion of the investigator, would pose a health risk to the subject if enrolled or could interfere with evaluation of the study drug or interpretation of study results
- •Donation of blood or blood products > 450 mL within 30 days of dosing.
- •Is an immediate family member or household member of study personnel
结局指标
主要结局
Proportion of subjects who achieve serum anti-hMPV and anti-PIV3 neutralizing antibody titers greater than the third quartile of the serum anti-hMPV and anti-PIV3 antibody titers overall distribution at baseline
时间窗: 1 month following the last dose administration
Frequency of solicited AEs (local and systemic reactogenicity events)
时间窗: 7 days following each dose administration
Frequency of unsolicited adverse events
时间窗: 28 days following each dose administration
Frequency of serious adverse events (SAE), adverse events of special interest (AESI), and medically-attended AEs
时间窗: one year following the last dose administration
Frequency of clinical laboratory adverse events
时间窗: 1 month following the last dose administration
Geometric mean titer (GMT) of the serum anti-hMPV and anti-PIV3 neutralizing antibodies
时间窗: 1 month following the last dose administration
Proportion of subjects with a ≥ 4-fold increase in serum anti-hMPV and anti-PIV3 neutralizing antibody titer from baseline to post-vaccination
时间窗: 1 month following the last dose administration
次要结局
- Geometric mean titer (GMT) of the serum anti-hMPV and anti-PIV3 neutralizing antibodies(6 months and 1 year following the last dose administration)
- Proportion of subjects with a ≥ 4-fold increase in serum anti-hMPV and anti-PIV3 neutralizing antibody titer from baseline to post-vaccination(6 months and 1 year following the last dose administration)
- Proportion of subjects who achieve serum anti-hMPV and anti-PIV3 neutralizing antibody titers greater than the third quartile of the serum anti-hMPV and anti-PIV3 antibody titers overall distribution at baseline(6 months and 1 year following the last dose administration)
研究者
研究点 (5)
Loading locations...
相似试验
已完成
1 期
Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior ExposureHuman Metapneumovirus and Human Parainfluenza InfectionNCT04144348ModernaTX, Inc.51
已完成
1 期
Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy AdultsCytomegalovirus InfectionNCT03382405ModernaTX, Inc.181
已完成
1 期
Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult SubjectsZika VirusNCT03014089ModernaTX, Inc.90
进行中（未招募）
2 期
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.Cytomegalovirus InfectionNCT05683457ModernaTX, Inc.84
已完成
1 期
A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years OldSARS-CoV-2InfluenzaNCT05375838ModernaTX, Inc.550